共 23 条
Characterization of monocyte-derived dendritic cells maturated with IFN-α
被引:17
作者:
Svane, IM
Nikolajsen, K
Walter, MR
Buus, S
Gad, M
Claesson, MH
Pedersen, AE
[1
]
机构:
[1] Univ Copenhagen, Panum Inst, Dept Med Anat A, Lab Cellular Immunol, DK-2200 Copenhagen, Denmark
[2] Herlev Univ Hosp, Dept Hematol, DK-2730 Herlev, Denmark
[3] Herlev Univ Hosp, Dept Oncol, DK-2730 Herlev, Denmark
[4] Univ Alabama, Dept Microbiol, Birmingham, AL 35294 USA
[5] Univ Copenhagen, Inst Med Microbiol & Immunol, DK-2200 Copenhagen, Denmark
关键词:
D O I:
10.1111/j.1365-3083.2006.01728.x
中图分类号:
R392 [医学免疫学];
Q939.91 [免疫学];
学科分类号:
100102 ;
摘要:
Dendritic cells (DC) are promising candidates for cancer immunotherapy. These cells can be generated from peripheral blood monocytes cultured with granulocyte macrophage-colony stimulating factor (GM-CSF) and interleukin-4 (IL-4). In order to obtain full functional capacity, maturation is required, but the most potent reagents such as LPS or polyriboinosinic polyribocytidylic acid (Poly I:C) are not approved for clinical use. We tested the ability of type I interferon (IFN) to induce such maturation. We found that 24-h IFN-alpha co-culture of day 7 monocyte-derived DC generated with GM-CSF and IL-4 induces increased numbers of DC positive for CD54 and CD40 together with the co-stimulatory molecule CD80 but not the activation marker CD83. Also, IFN-alpha maturation leads to an increase in IP-10 and MCP-1 chemokine secretion, but only a minor increase in IL-12p40 secretion. In line with this, maturation with IFN-alpha has only a small effect on induction of autologous T-cell stimulatory capacity of the DC. However, an increase in DC allogeneic T-cell stimulatory capacity was observed. These data suggest that IFN-alpha has a potential as a maturation agent used in DC-based cancer vaccine trials, but not as a single reagent.
引用
收藏
页码:217 / 222
页数:6
相关论文